Welcome to our dedicated page for Rapid Dose Thera news (Ticker: RDTCF), a resource for investors and traders seeking the latest updates and insights on Rapid Dose Thera stock.
Rapid Dose Therapeutics Corp. (RDTCF / CSE: DOSE) is a Canadian biotechnology and life sciences company centered on its QuickStrip™ oral thin-film drug delivery platform. The news flow around the company frequently combines product development updates with financing and corporate actions, giving investors insight into both its technology progress and its capital structure.
Readers of this news page can follow announcements on QuickStrip™-based initiatives, including nicotine-focused products such as QuickStrip™ Nicotine and NicStrip™, as well as harm reduction applications like the Replace+ sublingual cannabis strip developed with Eco Canadian Organic Inc. News releases have covered regulatory milestones such as a Health Canada submission for QuickStrip™ Nicotine in multiple dose strengths and details of a pharmacokinetic clinical study comparing nicotine absorption to combustible cigarettes.
In addition to product and partnership updates, Rapid Dose Therapeutics regularly reports on financing-related developments. These include private placement financings involving secured convertible notes and warrants, extensions of note maturities and warrant expiries, and the issuance of common shares to pay accrued interest on secured debt. The company has also disclosed shares-for-debt transactions with creditors and directors aimed at reducing outstanding liabilities.
By reviewing the news items linked on this page, investors and observers can track how Rapid Dose Therapeutics advances its QuickStrip™ technology across nicotine, cannabis, nutraceutical and pharmaceutical applications, while also monitoring share issuances, note terms and other corporate actions that affect its capital structure. This page is a central source for the company’s publicly released updates and disclosures.
Rapid Dose Therapeutics, in collaboration with McMaster University, has published a groundbreaking study on incorporating loratadine-cyclodextrin complexes into Oral Thin Films (OTF) for rapid drug delivery. This method increases the solubility of loratadine, commonly known as Claritin, allowing it to be effectively loaded into RDT's QuickStrip delivery platform. The study, published in the Journal of Pharmaceutical Sciences, funded by the Natural Sciences and Engineering Research Council of Canada and RDT, highlights significant enhancements in drug solubility and delivery. This collaboration aims to improve patient outcomes by offering an efficient alternative drug delivery route.